A Randomized Phase 2 Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Were Previously Treated With First Line Chemotherapy

Inclusion Criteria:

- Patients with non-small cell lung cancer with locally or advanced metastatic
disease(Stage IIIB or IV at entry) not amenable to curative therapy and who have
progressed after 1 line of chemotherapy

- Measureable disease as defined by response evaluation criteria in solid tumors
(RECIST)

- ECOG Performance status of 0 to 1

- Must make available any existing tumor tissue from the primary biopsy

- Patients with prior radiation may be eligible if they meet certain criteria

- Adequate bone marrow reserve and organ functioning

- Women must have a negative pregnancy test and must comply with a highly reliable
contraceptive method during and for 6 months after the treatment period. Must not be
breastfeeding

- Men must comply with a contraceptive regimen during and for 6 months after the
treatment period

Exclusion Criteria:

- Currently enrolled in or discontinued a clinical trial involving an investigational
drug/device within the last 30 days. Patients may be permitted to enter treatment
before the 30 day waiting period in special circumstances

- Pregnant or breastfeeding

- Serious concomitant systemic disorders that would compromise the safety of the
patient or the patient's ability to complete the study

- Second primary malignancy that could affect compliance with the protocol or
interpretation of the study results

- Known allergy or hypersensitivity to docetaxel, taxanes, LY2181308, oligonucleotides,
or any component of the formulations

- Patients with documented central nervous system or brain metastasis at the time of
study entry

- Pre-existing neuropathy equivalent to a common terminology criteria for adverse
events(CTCAE)code greater than or equal to 2